← Back to Search

Small Molecule Inhibitor

RMC-6236 for Cancer

Phase 1
Recruiting
Research Sponsored by Revolution Medicines, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing
Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Must not have
Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
Primary central nervous system (CNS) tumors
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2.5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called RMC-6236, which is taken by mouth and targets a protein called RAS. It is aimed at adults with advanced cancers that have specific mutations in the RAS protein. The drug works by blocking this protein, which helps stop the cancer cells from growing.

Who is the study for?
This trial is for adults with advanced solid tumors that have specific RAS mutations, who've already tried standard treatments. They need to be relatively healthy and active (ECOG status of 0 or 1), with good organ function. It's not for those with primary brain tumors, untreated brain metastases, issues absorbing oral meds, or other serious health problems.
What is being tested?
The study tests the safety and how well people tolerate RMC-6236, a new medication aimed at treating various types of cancer like lung and colorectal cancer that have certain genetic changes known as RAS mutations.
What are the potential side effects?
While the side effects of RMC-6236 are being studied in this trial and aren't fully known yet, they may include typical reactions to cancer medications such as nausea, fatigue, liver issues, skin reactions and potential allergic responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My advanced cancer has specific KRAS G12 or RAS mutations.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have issues with my digestive system that might affect my ability to take pills.
Select...
My cancer originated in the brain or spinal cord.
Select...
I have brain metastases that haven't been treated.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2.5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2.5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Disease Control Rate (DCR)
Duration of Response (DOR)
Overall Response Rate (ORR)
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Experimental: RMC-6236Experimental Treatment1 Intervention
Enrollment into dose exploration may be from any advanced solid tumor type with KRAS p.G12 mutations. Enrollment into dose expansion/optimization may be from groups consisting of patients with a single histotype/genotype (for example, KRAS G12-mutated NSCLC, PDAC, CRC, RAS mutant NSCLC, Melanoma, gynecological cancer or other solid tumors not previously specified). RAS mutant is defined as any nonsynonymous mutation of KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61)

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Non-Small Cell Lung Cancer (NSCLC) include targeted therapies, immunotherapies, and chemotherapy. Targeted therapies, such as EGFR inhibitors (e.g., osimertinib) and ALK inhibitors (e.g., crizotinib), work by specifically targeting genetic mutations that drive cancer growth, leading to more effective and personalized treatment. Immunotherapies, like pembrolizumab, enhance the body's immune response against cancer cells by targeting PD-1/PD-L1 pathways. Chemotherapy, using agents like pemetrexed and carboplatin, kills rapidly dividing cancer cells but can also affect normal cells. For patients with specific mutations like KRAS, emerging treatments such as RAS inhibitors (e.g., RMC-6236) are being studied to directly inhibit the RAS pathway, which is crucial for cancer cell proliferation and survival. Understanding these mechanisms allows for more precise and effective treatment strategies, improving outcomes and reducing side effects for NSCLC patients.

Find a Location

Who is running the clinical trial?

Revolution Medicines, Inc.Lead Sponsor
12 Previous Clinical Trials
2,740 Total Patients Enrolled

Media Library

RMC-6236 (Small Molecule Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05379985 — Phase 1
Colorectal Cancer Research Study Groups: Experimental: RMC-6236
Colorectal Cancer Clinical Trial 2023: RMC-6236 Highlights & Side Effects. Trial Name: NCT05379985 — Phase 1
RMC-6236 (Small Molecule Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05379985 — Phase 1
~222 spots leftby May 2026